NO ONE is expecting a breakthrough at the Tenth International Conference on AIDS this week in Yokohama, Japan.
In fact, much attention there may be on issues that many have thought were settled, such as the increasingly doubtful value of surrogate markers for disease progression and drug efficacy. The recent screeching halt in US plans for large-scale vaccine efficacy trials after disappointing preliminary results also promises lively debate (see also pp 488-489).
The conference itself is smaller this year, with about one third fewer abstracts accepted for oral and poster sessions than at last year's conference in Berlin, Germany. However, late submissions were being accepted and several late-breaker sessions are scheduled. "The goal of the organizers is to have as much up-to-date information as possible," says David Corkery of the conference's media liaison office for North America.
Attendance may also be down, with many who have attended in previous years